Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #251208 on Biotech Values
TheFinalCD
03/26/24 7:26 PM
#251224 RE: DewDiligence #251208
$VKTX conference call done- Summary 1) Safety profile similar to placebo even at high dose of 40mg2) Expecting higher dose cohorts, no disclosure on how many in ph23) High placebo effect due to small N and diarrhea in placebo arm4) Expecting placebo effect to move back…— Pharmdca (@Pharmdca) March 26, 2024
$VKTX conference call done- Summary 1) Safety profile similar to placebo even at high dose of 40mg2) Expecting higher dose cohorts, no disclosure on how many in ph23) High placebo effect due to small N and diarrhea in placebo arm4) Expecting placebo effect to move back…
$VKTX there’s seems to be no side effects with oral drug even at high doses Profile like placebo Remember- $VKTX is the only, only dual agonist and GIP agonist helping with counterbalancing GI side effects ✅✅— Pharmdca (@Pharmdca) March 26, 2024
$VKTX there’s seems to be no side effects with oral drug even at high doses Profile like placebo Remember- $VKTX is the only, only dual agonist and GIP agonist helping with counterbalancing GI side effects ✅✅
Mufaso
03/27/24 8:26 PM
#251264 RE: DewDiligence #251208
one has to wonder why an oral peptide drug for obesity would be a better option than a best-in-class oral small-molecule drug.